Addex Therapeutics Files 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Apr 18, 2024 · CIK: 1574232
Sentiment: neutral
Topics: filing, press-release
TL;DR
Addex Therapeutics dropped a new press release on 4/18, check Exhibit 99.1.
AI Summary
On April 18, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. This press release is attached as Exhibit 99.1 and is part of their reporting for April 2024.
Why It Matters
This filing indicates that Addex Therapeutics has issued a new press release, which may contain important updates for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain new financial or operational information that would inherently increase risk.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- April 18, 2024 (date) — Date of press release issuance
- Exhibit 99.1 (document) — Attached press release
- Form 6-K (document) — Filing type
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the issuance of a press release by Addex Therapeutics Ltd. on April 18, 2024, and to incorporate that press release by reference.
When was the press release issued?
The press release was issued on April 18, 2024.
Where can the press release be found?
The press release is attached to the Form 6-K filing as Exhibit 99.1 and is incorporated by reference.
What is the Commission File Number for Addex Therapeutics Ltd.?
The Commission File Number for Addex Therapeutics Ltd. is 001-39179.
Does Addex Therapeutics file annual reports under Form 20-F or Form 40-F?
Addex Therapeutics files annual reports under Form 20-F, as indicated by the checkmark next to it in the filing.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-04-18 06:05:06
Filing Documents
- f6k_041824.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 15KB
- 0001171843-24-002070.txt ( ) — 23KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On April 18, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated April 18, 2024 INCORPORATION BY REFERENCE Exhibits 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: April 18, 2024 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated April 18, 2024